首页> 外文期刊>Journal of Hematology and Oncology >Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
【24h】

Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

机译:浆母细胞性淋巴瘤患者的阶段,年龄和EBV状态影响结果:61例患者的临床病理分析

获取原文
           

摘要

Background Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. Patients and methods The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. Results Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p?=?0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p?=?0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p?=?0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p?=?0.047) but not OS (p?=?0.306). Notably, OS was adversely impacted by age ≥50 years (p?=?0.013), stage III or IV disease (p?=?<0.001), and lymph node involvement (p?=?0.008). Conclusions The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression.
机译:背景浆母细胞性淋巴瘤(PBL)是一种罕见的侵袭性肿瘤,具有淋巴样和浆细胞性分化,通常与免疫缺陷和不良预后有关。临床病理特征主要来自病例报告和小范围的结局分析。患者和方法回顾分析了61例PBL患者的人口统计学,临床病理特征和临床结局。结果患者的中位年龄为49岁(21-83岁),大多数(49/61; 80%)为男性。人类免疫缺陷病毒(HIV)状态可用于50例患者:20例HIV阳性和30例HIV阴性。 23名患者具有免疫能力。腹部/胃肠道不适是最常见的症状,在47名患者中有14名(30%)报告。在介绍时,43名患者中有24名(56%)患有III或IV期疾病。在57例病例中有40例(70%)检出了爱泼斯坦巴尔病毒(EBV)。在评估的10/15(67%)病例中发现了MYC重排,无论MYC重排状态如何,在所有评估的病例中均可见MYC过表达。 HIV阳性患者比HIV阴性患者明显年轻(中位年龄42岁vs. 58岁; p = 0.006)。与HIV阴性患者相比,HIV阳性患者患EBV阳性的可能性也显着更高(19 / 19,100%比15 / 29,52%; p = 0.002)。与接受超分级环磷酰胺,长春新碱,阿霉素和地塞米松(hyper-CVAD)的患者相比,接受CHOP化疗的患者的总生存期(OS)往往更高(p?=?0.078)。艾滋病毒状况对OS没有影响。 EBV阳性PBL患者的无事件生存期(EFS)更好(p?=?0.047),但OS则没有(p?=?0.306)。值得注意的是,OS受到年龄≥50岁(p = 0.013),III或IV期疾病(p <0.001)和淋巴结受累(p = 0.008)的不利影响。结论在PBL患者中,最重要的预后参数是年龄,阶段以及较小程度的EBV状态。在这项研究中,三分之二的PBL病例与MYC重排有关,均显示MYC过表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号